NasdaqCM:PLSEMedical Equipment
Pulse Biosciences (PLSE) Is Down 12.6% After Wider Losses And New Funding Plans - Has The Bull Case Changed?
Pulse Biosciences, Inc. reported a full-year 2025 net loss of US$72.78 million, widening from US$53.59 million in 2024, and filed new universal and ESOP-related shelf registrations alongside a reconfigured at-the-market common stock offering.
At the same time, FDA approval to begin a paroxysmal atrial fibrillation study with the nPulse Cardiac Catheter System and a planned thyroid cancer collaboration with The University of Texas MD Anderson Cancer Center underscore how the company is...